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Abstract
Objective: We have previously described the generation of coxsackievirus and
adenovirus receptor (aCAR)-targeted vector, and shown that intramuscular
delivery in mouse leg muscles resulted in specific retrograde transduction of
lumbar-motor neurons (MNs). Here, we utilized the aCAR-targeted vector to
investigate the in vivo neuroprotective effects of lentivirally expressed IGF-1 for
inducing neuronal survival and ameliorating the neuropathology and behavioral
phenotypes of the SOD1G93A mouse model of ALS. Methods: We produced cell
factories of IGF-1 expressing lentiviral vectors (LVs) bearing aCAR or Vesicular
Stomatitis Virus glycoprotein (VSV-G) on their surface so as to compare neu-
roprotection from MN transduced versus muscle transduced cells. We per-
formed intramuscular delivery of either aCAR IGF-1 or VSVG IGF-1 LVs into
key muscles of SOD1G93A mice prior to disease onset at day 28. Motor perfor-
mance, coordination and gait analysis were assessed weekly. Results: We
observed substantial therapeutic efficacy only with the aCAR IGF-1 LV pretreat-
ment with up to 50% extension of survival compared to controls. aCAR IGF-1
LV-treated animals retained muscle tone and had better motor performance
during their prolonged survival. Histological analysis of spinal cord samples at
end-stage further confirmed that aCAR IGF-1 LV treatment delays disease onset
by increasing MN survival compared with age-matched controls. Intrastriatal
injection of aCAR eGFP LV in rats leads to transduction of neurons and glia
locally and neurons in olfactory bulb distally. Interpretation: Our data are
indicative of the efficacy of the aCAR IGF-1 LV in this model and support its
candidacy for early noninvasive neuroprotective therapy in ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating adult-
onset progressive neurodegenerative disorder, character-
ized by the combined degeneration of upper and lower
motor neurons that reside in the spinal cord, brain stem,
and cortex. Affected individuals die 2–5 years following
diagnosis.1 ALS cases are mainly sporadic (SALS) and
only 10% exhibit an autosomal dominant mode of inheri-
tance (familial ALS or FALS).2 One-fifth of FALS cases
are caused by mutations in the Cu/Zn superoxide dismu-
tase-1 (SOD1) gene.3 Transgenic mice that overexpress
the mutant human SOD1 protein (various mutants with
G93A being the most aggressive) have been derived and
predominantly used as models of disease. These mice
develop a severe and progressive motor impairment lead-
ing to hind limb paralysis resembling ALS pathology in
humans.4
The IGF-1 family of growth factors (somatomedins)
includes three structurally related ligands (IGF-1, IGF-2
and insulin), their respective receptors, and at least six
IGF-1 binding proteins (IGFBP).5 They are produced in
multiple cells and exert different physiological roles by
binding to distinct tyrosine kinase receptors and activat-
ing multiple downstream signaling cascades.6 Insulin-like
growth factor 1 (IGF-1 or somatomedin C) has been
shown to interact with IGF-1R and can induce pleiotropic
effects, including neuroprotective ones, by inhibiting
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apoptosis.7 The majority of circulating IGF-1 is bound
and sequestered by IGFBPs, thus extending its half-life,
and controlling its distribution/bioavailability in various
tissues.
Gene delivery of neurotrophic molecules, including
IGF-1, shown to have a therapeutic effect on MN sur-
vival, could be a possible gene therapy strategy for ALS.8,9
In recent years, many studies have focused on gene deliv-
ery of growth factors to the central nervous system (CNS)
in order to slow disease progression in animal models of
ALS utilizing the intramuscular,10–13 intracerebral,14,15
intracerebroventricular16, and intraspinal17,18 routes of
administration. Despite the encouraging results of these
studies, subcutaneous delivery of recombinant human
insulin-like growth factor 1 IGF-1 (rhIGF-1) in ALS
patients had little effect in 3 clinical trials.19–21 Each of
these approaches has its own limitations which may
negate achieving efficacy in ALS patients. Thus, it is clear
that there is an urgent need to develop new therapeutic
strategies that could enhance translatability for ALS
patients.
We aimed at overcoming the limitations of existing
strategies for noninvasive CNS delivery, by engineering
HIV-1 vectors with tropism to spinal cord MNs delivered
via the neuromuscular junction (NMJ).22 We have previ-
ously described the generation of HIV-1-based coxsack-
ievirus and adenovirus receptor (aCAR)-targeted vector,
and shown that intramuscular (i.m.) delivery of aCAR-
targeted vector in mouse leg muscles results in specific
retrograde transduction of lumbar MNs.22 Our approach
is based on antibody mediated cell-specific targeting and
involves modification of the viral vector surface to redi-
rect target specificity.23 More specifically, a binding-defi-
cient version of the a-virus Sindbis glycoprotein is used
to pseudotype lentiviral vectors and to mediate fusion of
viral and endosomal membrane, while the specificity is
determined by an antibody (here the aCAR) chosen to
recognize a specific surface receptor of the desired cell
type.23,24
In this study, we used the aCAR-targeted LV to deliver
therapeutics to SOD1G93A ALS mice. We chose the
human class I IGF-1 which has previously been reported
to prolong survival in transgenic mouse ALS models upon
retrograde delivery from the muscle to spinal cord
MNs.12 Utilizing the aCAR-targeted LV, we investigated
in vivo the neuroprotective effects of lentivirally expressed
IGF-1 for inducing neuronal survival and delaying neu-
ropathology and behavioral phenotypes associated with
the SOD1G93A mouse model of ALS. Upon i.m. delivery,
prior to onset of disease (day 28), aCAR IGF-1 LV is ret-
rogradely transported through the synapse via the axon to
the nucleus of spinal MNs, where the secreted IGF-1 can
act in an autocrine manner on IGF-1 receptors on MNs
to induce neuroprotective downstream signaling and/or
in a paracrine on other cells. We demonstrate substantial
therapeutic efficacy in vivo with aCAR IGF-1 LV pretreat-
ment which is linked to improved motor performance.
Finally, histological analysis of spinal cord samples at end
point shows that i.m. delivery of aCAR IGF-1 LV delays
disease onset and increases motor neuron survival com-
pared with age-matched controls. This vector exhibits
cross-species transduction in the rat CNS.
Methods and Materials
Production of LVs
HEK 293T cells, obtained from ATCC, were maintained in
a 5% CO2 environment in Dulbecco’s modified Eagle’s
medium (Sigma, UK), with 10% Newborn Calf Serum
(Heat Inactivated, Sigma, Dorset, UK), 1% Penicillin/
Streptomycin and 1% L-glutamine (Sigma, UK). A total of
6 9 108 cells 293T cells were seeded onto a cell factory
with 10 layers CF-10 (VWR, Leicestershire, UK). A DNA
plasmid manufacturing company (Plasmid Factory, Biele-
feld, Germany) was used for production of research grade
supercoiled DNA. The complementary DNA for human
insulin-like growth factor-1 (IGF-1) was encoding the
Class 1 IGF-1Ea12 was codon optimized for human and
synthesized by Gene Art (Life Sciences, Paisley, UK).
Thereafter, 24 h upon seeding 293T cells at 80% conflu-
ence were transfected with 0.6 mg vector plasmid
(pRRLsincppt-CMV-IGF-1-WPRE), 0.3 mg of each of the
packaging vector plasmids expressing the HIV-1 gag/pol
gene (pMD2-LgpRRE), HIV-1 Rev (pRSV-Rev) (kindly
provided by Professor James Uney, University of Bristol,
Bristol, UK) together with 0.3 mg of each of paIgab,
pSINmu and paCAR described in22 following the addition
of 2.5 mol/L CaCl2. For VSVG IGF-1, LVs cells were
transfected with 0.6 mg therapeutic vector plasmid
(pRRLsincppt-CMV-IGF-1-WPRE), 0.6 mg of the packag-
ing vector plasmid pMD2-LgpRRE, 0.12 mg of the packag-
ing vector plasmid pRSV-Rev, and 0.3 mg the VSV-G
envelope plasmids (pMD2-VSV-G). Then the 16 h post-
transfection medium was replaced with fresh low serum
(2%) media supplemented with 10 mmol/L sodium buty-
rate; 72 h posttransfection, the viral supernatant was col-
lected and filtered through a 0.20-lm-pore size filter.
Preparations were concentrated by centrifugation at
6000 rpm for 12–16 h at 4°C (Beckman Coulter Avanti J-
E, F500 rotor, Beckman Coulter, High Wycombe, UK).
The pellet was resuspended in ice-cold phosphate-buffered
saline (PBS), and was further concentrated by ultracen-
trifugation for 90 min at 20,000 rpm, 10°C (Beckman
Coulter Optima L-80XP). The pellet was resuspended in
300 lL ice-cold TSSM formulation buffer (20 mmol/L
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Tromethamine, 100 mmol/L NaCl, 10 mg/mL sucrose and
10 mg/mL mannitol) (2000-fold concentration). Viral titer
was determined as described before.22
Single plasmid transfections
Single plasmid lipofectamine transfections were performed
utilizing the Lipofectamine LTX and Plus Reagent kit (Life
Technologies, Paisley, UK). Briefly, 24 h prior to transfec-
tion HEK 293T cells were seeded onto 6-well plates
(1 9 106 cells/well). Next day, an hour prior to transfec-
tion medium was replaced with low serum (2%) DMEM
medium and 2.5 lg of supercoiled plasmid DNA was
diluted in a mixture of OPTI-MEM solution, PLUS Reagent
and LTX Reagent according to manufacturer’s instructions.
Transfection solution was added dropwise directly onto the
cells and incubated at 37°C, 5% CO2 for 40 h.
Western blot
For cell lysate preparation, a monolayer of packaging cells
were lysed with RIPA buffer (89900, Thermo Scientific,
Paisley, UK) supplemented with 19 proteinase inhibitor
mixture (E1014-5KU, Thermo Scientific). Lysates were
cleared by centrifuging at 15,000 rpm for 30 min at 4°C
and supernatant was kept at 80°C. Prior to SDS-PAGE
analysis, protein concentration in the cell lysate samples
was determined by BCA (Bradford and bicinconinic Acid)
Protein assay (23227, Thermo Scientific). Boiled samples in
29 SDS loading buffer were resolved on a 5–12% SDS-
polyacrylamide gel (SDS-PAGE). Upon electrophoresis, the
separated proteins were transferred onto a nitrocellulose
membrane (Hybond-ECL, GE healthcare, Amersham, UK).
The resulting blots were blocked in 5% milk solution in 19
PBS-Tween (0.1% v/v) overnight at 4°C. The next day the
blots were incubated with relevant primary antibodies. To
detect the HA tag, blots were incubated with anti-HA-HRP
(1: 5000 in 5% milk PBS-Tween 0.1% v/v, Miltenyi Biotec)
for 1.5 h at room temperature. To detect human IGF-1,
membranes were incubated with goat anti-human IGF-1
(2 lg/mL in 5% milk PBS-Tween 0.1% v/v, ab106836
Abcam, Cambridge, UK) for 1.5 h at room temperature.
Mouse mAb to GAPDH protein (1:1000, Santa Cruz, Hei-
delberg, Germany) was used as loading control. Secondary
antibodies used were a 1:3000 or (in 0.5% milk PBS-Tween
0.1% v/v) of relevant HRP-linked anti-IgG, followed by
detection, using ECL reagent (Pierce, Thermo Scientific).
Enzyme linked immunosorbent assay of
human IGF-1
Protein from animal tissue was isolated by rapidly dissect-
ing the tissue on ice and immediately homogenizing,
using either the RIPA buffer (89900, Thermo Scientific)
or the Tissue Protein Extraction Reagent (Pierce, Rock-
ford, IL) supplemented with 19 proteinase inhibitor mix-
ture (E1014-5KU, Thermo Scientific). Enzyme-linked
immunosorbent assay for human IGF-1 was performed in
duplicate, using the Duo Set ELISA kit (DY291; R&D Sys-
tems, Abingdon, UK) in combination with MSD platform
(Mesoscale Diagnostics, MD, Maryland, USA). Protein
homogenates were diluted 2000-fold for cells and twofold
for tissue, using the assay diluent and the assays per-
formed following the MSD recommendations.
Animals
All animal procedures were approved by the local Ethical
Committee and performed in accordance with United
Kingdom Animals Scientific Procedures Act (1986) and
associated guidelines. All efforts were made to minimize
the number of animals used and the suffering. Animals
were supplied by Charles River, UK and housed under
a 12 h light/dark cycle with food and water available
ad libitum.
The congenic C57BL/6J Tg (SOD1 G93A)1Gur(G93A-
SOD1) mice (Jackson Laboratory, Bar Harbor, ME) were
used25 and were backcrossed onto the wild-type C57BL/6
mouse background (Charles River Laboratories, Wilming-
ton, MA) for >10 generations. A priori power analysis
revealed that 12 animals per group (both males and
females) was a sufficient sample size in order to detect a
medium effect with 80% power.26 Transgenic mice were
genotyped according to the Jackson Laboratory protocols
and were organized in subgroups of 18 (6 animals per
group; (i) no treatment or mock (aCAR eGFP LV), (ii)
aCAR IGF-1 LV, (iii) VSVG IGF-1 LV), and they were
age matched and litter matched wherever possible.
Human SOD1G93A gene copy number was assessed27 and
remained stable across generations (Copy number 25+/-
1.2 copies hSOD1G93A; remained stable across mice used,
F3–F6). We found only one mouse with an altered SOD1
gene copy number and this mouse was removed from the
study.
LV delivery
For mice injections, a total volume of 100 lL of lentiviral
vector solution was delivered via single bilateral intramus-
cular injection (28 days of age  1 day) in key muscle
groups (gastrocnemius muscle [GA], 20 lL; tibialis ante-
rior muscles (TA), 15 lL; intercostal muscles 10 lL; tri-
ceps muscles 5 lL) with a micro-fine 29G insulin needle,
under general anesthesia with isofluorane.
For weight, survival, rotarod, and a catwalk perfor-
mance, 60 SOD1G93A mice (aCAR IGF-1 LV: n = 24 in
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total, n = 12 males, n = 12 females; VSVG IGF-1 LV:
n = 12 in total, n = 6 males, n = 6 females; no treatment:
n = 12 in total n = 6 males, n = 6 females; aCAR eGFP
LV: n = 12 in total, n = 6 males, n = 6 females) were
assessed. For motor neuron counts 16 SOD1G93A mice
(aCAR IGF-1 LV: n = 8 in total, n = 4 males, n = 4
females; VSVG IGF-1: n = 8 in total, n = 4 males, n = 4
females; aCAR eGFP LV: n = 4 in total; n = 2 males,
n = 2 females; no treatment: n = 4 in total; n = 2 males,
n = 2 females) were assessed.
Because aCAR eGFP LV and nontreated mice had the same
survival and performed equivalently on the behavioral assess-
ments they were presented in analysis as one group named as
nontreated (n = 24; n = 12 males, n = 12 females).
For intrastriatal injections in rats, in vivo application of
aCAR-targeted vector and control in CNS was performed
to examine the neurotropism of the lentiviral preparations.
In in vivo intrastriatal applications, male Wistar rats,
weighing 200–250 gr were used. Animals were placed in a
stereotactic frame (Taxic-6000, World Precision Instru-
ments, Hitchin, UK) with the nose bar set at 3.3 mm
under general anesthesia. The scalp was cut and retracted
to expose the skull. Craniotomy was performed by drilling
directly above the target region, to expose the pial surface.
One single injection was directed into the right striatum
using the stereotactic coordinates relative to bregma:
anteroposterior, 0.5 mm; mediolateral, 3.0 mm; dorsoven-
tral, 5.0 mm. Animals usually received 4.0 lL of pseudo-
typed LV vectors with a biological titer within the scale of
1 9 109 TU/mL via a 32G blunt needle, using an infusion
pump (UltramicropumpIII and Micro4 Controller, World
Precision Instruments) at a stable flow rate of 0.2 lL/min
over 20 min. Upon delivery, needle was allowed to remain
on site for additional 5 min prior to slow retraction.
Behavioural and survival analysis
Behavioral assessment and all in vivo tests were carried out
from 65 days of age until 150 days of age blinded to treat-
ment. All animals were weighted weekly until they reached
110 days of age at which point they were weighted daily
until end stage. Motor coordination and performance were
recorded using the Ugo Basile ROTA-ROD for mice (Ugo
Basile, Varese, Italy). Each weekly session consisted of three
trials on the rotarod, which was set to accelerate from
5 rpm (rotations per minute), and the latency to fall was
recorded in seconds. The maximum time depicting no
motor impairment was defined as 300 sec. The time each
mouse remained on the rod was registered. Footprint anal-
ysis was also performed every 10 days. Mouse hind- and
fore-paws were covered with red and green paint, respec-
tively, to record walking patterns during continuous loco-
motion, and stride length was measured. Gait analysis was
also performed using the automated footprint recording
Catwalk system 10.5 (Noldus Information Technology,
Wageningen, The Netherlands) every 10 days. Briefly, each
animal was allowed to run from one side of the glass plate
to the other and a camera placed underneath the glass plate
recorded the video image of each run. Survival analysis was
performed using the Kaplan–Meier survival analysis. End
stage was defined the point at which the animals could no
longer “right” themselves within 30 sec after being placed
on their back.
Perfusion and tissue processing
When mice reached the endpoint (loss of righting reflex for
30 sec), they were killed by intraperitoneal injection of
200 mg/kg of sodium pentobarbitone, and then transcar-
dially perfused with 20 mL saline (0.9% w/v NaCl) supple-
mented with heparin 5 units/mL (Sigma) followed by
20 mL of 4% (w/vol) paraformaldehyde (PFA, Sigma
Aldrich) in PBS. Spinal cord, TA, GA, intercostal, and triceps
muscles were removed and either postfixed for 4 h in 4%
PFA, followed by cryoprotection in 10% glycerol and 20%
sucrose in PBS for at least 72 h or snap frozen in liquid
nitrogen and stored at 80°C until further analysis. Fixed
tissues were subsequently embedded and frozen in OCT
(Surgipath FSC22; Leica Microsystems, Wetzlar, Germany).
Twenty micrometer coronal sections from the sacral plexus
through the entire lumbar and thoracic parts of the spinal
cord were cut using a cryostat (Leica Microsystems),
mounted on gelatinized slides, and stored at 20°C.
For western blot analysis upon euthanasia, mice were
perfused with 20 mL saline (0.9% w/v NaCl) plus hep-
arin. The same tissues, as mentioned above, were
removed and snap frozen using liquid nitrogen.
Rats were killed 3 weeks postinjection by intraperi-
toneal injection of 200 mg/kg of sodium pentobarbitone,
transcardially perfused with 200 mL saline (0.9% w/v
NaCl) plus heparin, followed by 250 mL of 4% PFA in
PBS. Brains were removed and postfixed for 4 h in 4%
PFA, followed by cryoprotection in 10% glycerol and
20% sucrose in PBS for at least 72 h. The brain was sub-
sequently embedded and frozen in OCT (Surgipath
FSC22; Leica Microsystems).
Motor neuron quantification
Sections were processed for cresyl violet staining stain
(0.1% Cresyl Fast Violet; BDH, Lutterworth, UK). Surviv-
ing motor neurons were counted in every 10th section
under a light microscope at 920 magnification in order
to avoid repetitive counting (n = 24 mice [eight per
group]). MN counting was performed blindly between
different groups and sexes. Only motor neurons with a
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clearly identifiable nucleus and nucleolus and a cell soma
were counted. MN quantification was performed in spinal
cord sections extracted from animals at end stage.
Immunohistochemisty
Immunohistochemistry was performed on slide mounted
spinal cord sections. Tissue was permeabilized for 1 h
with PBS-containing 10% donkey serum and 0.1% Tri-
ton-X100. Antibodies to eGFP (1:500, ab290, Abcam),
ChAT (1:50 AB114P, Millipore, Watford, UK) were
diluted in the same buffer and placed on sections for
72 h at 4°C. Sections were then blocked for 30 min prior
to incubating for 3 h at room temperature with donkey
anti-rabbit, anti-goat secondary antibodies conjugated
with AlexaFluor 488 or 594 (1:500; Invitrogen, Paisley,
UK), respectively. Sections were mounted with ProLong
anti-fade aqueous mounting medium (Invitrogen).
For rat brain tissue, 30 lm coronal sections from the
olfactory bulb (OB), through the entire striatum, globus
pallidus and substantia nigra (SN) were cut using a cryo-
stat (Leica Microsystems), mounted on poly-L-lysine
coated slides, and stored at 20°C. Immunohistochem-
istry was performed on slide mounted brain sections. The
tissue was permeabilized and blocked for 1 h with PBS-
containing 10% donkey serum and 0.1% Triton-X100.
Primary antibodies to eGFP (1:500, ab290, Abcam), NeuN
(1:100, MAB377, Millipore) and GFAP (1:400, MAB360,
Millipore) were diluted in the same buffer and applied on
sections for 48 h at 4°C. Sections were then washed three
times with PBS for 10 min, shaking gently and blocked
for 30 min prior to incubation with secondary fluores-
cently labeled antibodies (for 3 h at room temperature).
ProLong anti-fade aqueous mounting medium with DAPI
was used to apply coverslips (Invitrogen).
Statistical analysis
Survival analysis of the SOD1G93A mice was performed by
Kaplan–Meier analysis, which generates a v2 value to test for
significance. All other tests not involved in survival analysis
were performed by multi-way analysis of variance followed
by a Bonferroni post hoc analysis of means differences
between groups (GraphPad Prism Software, San Diego, CA).
Results
Generation of aCAR IGF-1 and control LVs
In the current study we utilized the aCAR-targeted len-
tiviral vector (aCAR-targeted LV) to deliver therapeutics
to SOD1G93A mice. We chose the human class I Insulin
like growth factor 1 (IGF-1Ea), which has previously been
reported to prolong survival in transgenic mouse ALS
models through viral mediated delivery applied dis-
tally.12,14,16 Towards this end we cloned a codon-
optimized version of the human class 1 IGF-1 (class 1
IGF-1Ea) into an HIV-1-based lentiviral vector under the
control of the human cytomegalovirus (CMV) enhancer
and promoter (Fig. 1A). We inserted an HA tag on the 5
prime end of IGF-1. As a control we used aCAR-targeted
LV vector expressing the enhanced green fluorescent pro-
tein (eGFP), a system which was previously found and
reconfirmed here using cell factory preparations to be
effective for targeted expression in spinal cord MNs after
TA injections22 (Fig. 1A). Human IGF-1 expression was
assessed via western blot in total protein extracts follow-
ing lipofectamine transfections of either the pRRLsincppt-
CMV-IGF1-WPRE therapeutic or the pRRLsincppt-CMV-
eGFP-WPRE construct in HEK293T cells (Fig. 1B).
Human IGF-1 levels were measured in homogenates and
supernatant of cells transfected with HIV-1 326-
pRRLsincppt-CMV-IGF-1-WPRE and 326-pRRLsincppt-
CMV-eGFP-WPRE plasmids using an enzyme-linked
immunosorbent assay (ELISA) that recognized the
expressed human IGF-1 (Fig. 1C). Detectable levels of
human IGF-1 were noted in both homogenates (>2 lg/lL)
and supernatant (>1 lg/lL) of cells transfected with
the therapeutic expression plasmid pRRLsincppt-CMV-
IGF-1-WPRE. Highest levels were found in homogenates
of cells transfected with pRRLsincppt-CMV-IGF-1-WPRE.
Negligible levels of human IGF-1 were detected only in
the lysates of cells transfected with the control 326-
pRRLsincppt-CMV-eGFP-WPRE expression plasmid, with
background levels detected <20 ng/lL.
To assess the expression levels of lentivirally expressed
IGF-1 we infected HEK 293T cells with LVs expressing the
human IGF-1 at MOI 50. Cells transduced with LVs
expressing eGFP were used as control. Using an ELISA
we were able to detect human IGF-1 in lysates (mean IGF-1
levels 732.14 ng/mL) and secreted IGF-1 in the supernatant
of cells transduced (mean IGF-1 levels 7591.88 ng/mL)
with LVs expressing the human IGF-1 (Fig. 1D). No IGF-1
was detected in either lysates or supernatants of cells trans-
duced with control eGFP-expressing LVs (mean back-
ground levels at 220.15 ng/mL for cell lysates).
These data demonstrate that the synthetic human
IGF1-Ea we cloned in HIV-1 is efficiently expressed and
secreted upon infection of HEK293T cells with IGF-1-ex-
pressing LVs.
We subsequently generated a therapeutic aCAR-tar-
geted LV encoding the same secretable codon-optimized
human IGF-1 under the same promoter. By utilizing cell
factories we produced high titer preparations of therapeu-
tic-targeted aCAR IGF-1 LVs. We also produced Vesicular
Stomatitis Virus glycoprotein (VSV-G) pseudotyped LVs
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expressing human IGF-1 to assess neuroprotection result-
ing from muscle-produced IGF-1.
Intramuscular delivery of aCAR IGF-1 LV
prolongs survival of SOD1G93A animals
To investigate the neuroprotective effects of aCAR IGF-1
LV on ALS pathogenesis, we performed single bilateral
delivery of either aCAR-targeted or control VSV-G pseu-
dotyped LVs expressing IGF-1 into key muscle groups of
both male and female SOD1G93A mice (n = 24 animals/
group) predisease onset at 28 days of age (Table S1).
Impact of the different treatments on survival of
SOD1G93A mice was analyzed by Kaplan–Meier survival
curves. Treated mice were monitored up to end stage and
compared with control groups. Onset of disease (mea-
sured by weight loss from denervation-induced muscle
atrophy) was significantly delayed by a median of 32 days
in aCAR IGF-1-treated mice when compared with non-
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P < 0.0001 Wilcoxon, signed-rank test) and by 9 days
when compared with VSVG IGF-1-treated mice (Fig. 2A;
VSVG IGF-1-treated, 141.5 days P = 0.0133, Wilcoxon
signed-rank test). When male aCAR IGF-1-treated
SOD1G93A cohorts were analyzed separately disease onset
was significantly delayed by 29.5 days when compared
with nontreated control male mice (Fig. S1A; 145 vs.
115.5 days P < 0.0001 Wilcoxon, signed-rank test) and by
6 days versus VSVG IGF-1-treated mice; however, the
later delay was not significant. In the female cohorts,
treatment with aCAR IGF-1 significantly delayed disease
onset by 32.5 days when compared with nontreated con-
trol female mice (Fig. S1; 153 vs. 120.5, P < 0.0001) and
by 9 days when compared with VSVG IGF-1-treated mice
(Fig. S1; 153 vs. 144, P = 0.0087). We observed an 8-day
difference in median disease onset between female and
male aCAR IGF-1 LV-treated cohorts, however this differ-
ence was not significant (females: 153 days vs. males:
145 days; v2 = 1.711, P = 0.1908).
Survival analysis showed that mice treated with targeted
therapeutic aCAR IGF-1 LV showed a 14-day increase in
median lifespan when compared with nontreated control
mice (Fig. 2B; 169 vs. 155; log-rank test, v2 = 18.15,
P < 0.0001) and 9 days when compared with VSVG IGF-
1-treated mice (Fig. 2B; 169 vs. 160; log-rank test,
v2 = 6.308, P = 0.012). There was no difference in sur-
vival between nontreated and VSVG IGF-1-treated control
mice. When male and female cohorts were analyzed sepa-
rately aCAR IGF-1 LV treatment significantly increased
median lifespan in both male and females when compared
with nontreated control cohorts by 12 and 8 days
(Fig. S1B; males, log-rank test, v2 = 8.513, P = 0.0035;
females v2 = 7.913, P = 0.0049), respectively. When aCAR
IGF-1 LV-treated cohorts were compared with VSVG
IGF-1-treated male and female mice, median lifespan was
significantly increased in both female and male mice
(Fig. S1B; females: 7.5 days; log-rank test, v2 = 4.756,
P = 0.0292; males: 4 days; log-rank test, v2 = 4.518,
P = 0.0335). When we compared median survival between
female and male aCAR IGF-1 LV-treated cohorts, we
found no significant difference (females: 168 days vs.
males: 170 days; log-rank test, v2 = 0.1008, P = 0.7509).
Interestingly we observed some variability in survival
with two female mice surviving up to 197 and 198 days
and 1 male mouse up to 240 days, which accounts for
extension of survival of up to 27% and 54%, respectively,
compared with VSVG IGF-1 LV and nontreated controls.
Weekly body weight measurements revealed a signifi-
cantly slower loss of body weight in aCAR IGF-1-treated
mice from 135 days onward. P28 aCAR IGF-1 LV-treated
female mice maintained their weights when compared
with age-matched controls (Fig. 2C). More specifically,
aCAR IGF-1 LV treatment significantly delayed weight
decline at days 136–145 when compared to nontreated
controls and at days 152 (P < 0.1) and from day 155
onwards (P < 0.001) when compared with VSVG IGF-1
LV-treated mice. In male mice aCAR IGF-1 LV treatment
significantly delayed weight decline compared with non-
treated male mice from day 145 (P < 0.01), but no signif-
icant effect was found versus the VSVG IGF-1 LV-treated
male control mice (Fig. 2D).
aCAR IGF-1 LV improves motor function and
coordination in SOD1G93A mice
Motor performance, coordination and gait analysis were
assessed weekly from day 65 onwards, for both IGF-1-trea-
ted and control groups (Fig. 3). SOD1G93A mice were
Figure 1. Generation and characterization of targeted lentiviral vectors. (A) Experimental design for overexpression of IGF-1 or eGFP in MNs of
SOD1G93A mice. Schematic drawing of the plasmids used for production of spinal cord MN-targeted aCAR LVs produced in cell factories. aCAR-
targeted vectors were generated by six-plasmid co-transfection using the pMD2-LgpRRE and pRSV-Rev packaging plasmids, the paCAR plasmid,
Igab plasmid required for surface expression of antibody molecules, SINmu(SGN) envelope plasmid, and the pRRLsincppt-CMV-IGF-1-WPRE or
pRRLsincppt-CMV-eGFP-WPRE genome plasmid in HEK293T cells. The human codon optimized sequence that encodes the class 1 insulin-like
growth factor-1, IGF-1Ea was cloned into the pRRLsincppt-CMV-WPRE HIV-1 genome plasmid under the control of human cytomegalovirus
(CMV) immediate early enhancer and promoter. Following uptake by CAR receptors at the NMJ vectors become retrogradely transported and
transduce spinal motor neurons either with eGFP or IGF-1 which following secretion binds at surface expressed receptors and activates
downstream signaling cascades mediating neuroprotection. eGFP expression following injection into TA muscle of mice results in specific
retrograde transduction of MNs in dorsolateral nucleus in L3-L5 of spinal cord. Scale bar: 50 lm. (B) Western blot analysis of total protein extracts
following lipofectamine transfections of pRRLsincppt-CMV-IGF1-WPRE therapeutic or pRRLsincppt-CMV-eGFP-WPRE control construct in HEK293T
cells. Cell lysates of transfected HEK293T cells and nontransfected controls were subjected to lysates from nontransfected cells and cells
transfected with pRRLsincppt-CMV-eGFP-WPRE construct, both lacking the human IGF-1 and the HA-tag, served as controls. Human IGF-1
(middle panel) and HA tag (top panel) were, as expected, detected in lysates of cells transfected only with the targeted therapeutic constructs.
Lower panel: Loading control. (C) Human IGF-1 levels in homogenates and supernatant of cells transfected with HIV-1 pRRLsincppt-CMV-IGF-1-
WPRE and pRRLsincppt-CMV-eGFP-WPRE plasmids were measured by enzyme-linked immunosorbent assay. (D) Human IGF-1 levels in
homogenates and supernatant of cells transduced with LVs expressing either eGFP or human IGF-1Ea or genes at an MOI 50 and noninfected
cells were measured by enzyme-linked immunosorbent assay. CAR, coxsackievirus and adenovirus receptor; CMV, cytomegalovirus promoter;
eGFP, enhanced GFP; R, HIV-1 viral protein R; LTR, long-term repeats; Ψ, Retroviral Psi packaging element; RRE, HIV-1 Rev response element;
cPPT, central polypurine tract; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element; DU3, mutated viral enhancer region.
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tested weekly for rotarod coordination and their perfor-
mance was analyzed over time for female (n = 12 per
group) and male (n = 12 per group) cohorts (Fig. 3A).
Rotarod tests showed that aCAR IGF-1 LV-treated female
mice maintained their ability to coordinate their move-

















































































Figure 2. aCAR IGF-1 LV improves survival in SOD1G93A mice. (A) Kaplan–Meier survival analysis of aCAR IGF-1 LV and VSVG IGF-1 LV-treated
and nontreated control female and male SOD1G93A mice. Treated mice were monitored up to end-stage and compared to nontreated control
group. End stage was defined as the point at which the animals could no longer “right” themselves within 30 sec after being placed on their
back. Survival analysis showed that the median lifespan of SOD1G93A mice was extended by 8 days in aCAR-IGF-1 LV-treated mice (Kaplan–Meier
plot; n = 12 mice per group, P < 0.001, v2 = 14.92). (B) Comparison of mean age of survival in all groups. Mean survival was significantly
improved in aCAR IGF-1 LV-treated compared with both control groups (one-way ANOVA, Tukey’s Multiple Comparison Test, P < 0.05) (C) P28
aCAR IGF-1 LV-treated female mice maintained their weight compared with age-matched controls. aCAR IGF-1 LV significantly delayed weight
decline compared with nontreated controls at days 136, 140–145 (**P < 0.01) and at day 160 and onwards (*P < 0.05) and compared to VSVG
IGF-1 LV-treated mice at days 152 (*P < 0.05) and from d155 onward (*P < 0.05). (D) Compared to VSVG IGF-1 LV-treated male mice controls,
aCAR IGF-1 LV had no effect on weight decline. aCAR IGF-1 LV significantly delayed weight decline compared to nontreated males mice from
day 145 (**P < 0.01, ***P < 0.001). aCAR IGF-1 LV-treated mice (n = 24) are shown in magenta, VSVG-IGF-1 LV-treated mice (n = 12) are
shown in light blue and nontreated control group in black.
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and nontreated mice starting from 130 days until end
stage (P < 0.05 from 130 days of age onward, n = 12 ani-
mals per group). However, aCAR IGF-1 LV-treated male
mice had significantly better rotarod performance than
nontreated control animals starting from 130 days onward
(P < 0.05, n = 12 animals per group), but no significant
difference was observed between aCAR IGF-1 LV and
VSVG IGF-1 LV-treated male mice. Manual footprint
analysis showed impaired walking patterns in control ani-
mals compared with aged-matched aCAR IGF-1 LV-trea-
ted mice from 115 days onwards (P < 0.05, from 115 day
onward, n = 12 animals per group) (Fig. 3B). Representa-
tive walking patterns from manual footprint analysis are
presented in Figure S2B. Results were confirmed on a sep-
arate cohort of mice where digital footprint analysis also
demonstrated impaired walking patterns in control ani-
mals compared with aged-matched aCAR IGF-1 LV-trea-
ted mice, but this time from 125 days onwards (Fig. 3C).
Representative footprints of late symptomatic stage mice
showed that nontreated SOD1G93A mice dragged their
hind legs, whereas aCAR IGF-1 LV-treated mice showed
minor defects in coordination of steps (Fig. S2A).
Overall, the administration of MN-targeted aCAR IGF-
1 LV significantly delayed the onset of disease as assessed
by rotarod performance tests, gait analysis and body
weight compared with nontreated and VSVG IGF-1 LV-
treated control SOD1G93A mice. Interestingly, there was
no statistical difference observed between male mice trea-
ted with aCAR IGF-1 LV and VSVG IGF-1 LV in both
rotarod test and body weight assessment other than one
time point at 155 days of age in body weight measure-
ments of surviving mice (Fig. 2D).
Intramuscular application of aCAR IGF-1 LV
resulted in motor neuron protection in
SOD1G93A mice
ALS has been associated with progressive and severe spinal
motor neuron atrophy and cell death.28 Targeted aCAR
IGF-1 LV was assessed for its ability to exert a neuropro-
tective effect and consequently increase motor neuron sur-
vival in SOD1G93A mice compared with nontreated control
animals when applied preonset of disease at 28 days of
age. Lumbar and thoracic regions of spinal cord were
labeled and evaluated for surviving MNs at end stage.
MNs were identified by their location within the spinal
cord, their morphology and their size. Histological evalua-
tion of end-stage lumbar spinal cord samples revealed loss
and atrophy of MNs in nontreated mice (Fig. 4A top panel
and Fig. 4B) and VSVG IGF-1 LV compared with large-
sized surviving MNs observed in aCAR IGF-1 LV-treated
SOD1G93A mice (Fig. 4A lower panel). Surviving MNs in
treated animals appeared dark stained after labeling with
Nissl dye, with a lighter stained nucleus and a very dark
and well-defined nucleolus. Gene transfer at end-stage
aCAR eGFP injected SOD1G93A mice was assessed by con-
focal microscopy and was evident mainly in axons and less
so in some of the remaining motor neurons of ventral
horn (Fig. 4B). To assess survival of MNs we performed
total cell counts of surviving MNs in both thoracic and
lumbar parts of spinal cord obtained from nontreated,
VSVG IGF-1 LV and aCAR IGF-1 LV-treated animals at
end-stage of the disease (both male and females). aCAR
IGF-1 LV-treated animals showed a significant preserva-
tion of MNs in the lumbar part of the spinal cord com-
pared with both nontreated and VSVG IGF-1 LV mice
(mean MN counts 18.55  1.22 vs. 12  2.12 and
6.80  1.20, respectively, P = 0.0026) (Fig. 4C). aCAR
IGF-1 LV-treated animals displayed higher numbers of
surviving MNs per section compared with nontreated and
VSVG IGF-1 injected mice (mean MN counts
17.43  1.44 vs. 10  1.12 and 6.85  1.75, respectively;
P = 0.018) also in the thoracic region of the spinal cord
(Fig. 4C). To determine whether survival of spinal cord
MNs was due to neuroprotection derived from lentivirally
expressed IGF-1 we measured the levels of human IGF-1
in homogenates of end-stage lumbar spinal cord samples
from nontreated and aCAR IGF-1 LV-treated animals.
Toward this end, we used an ELISA that recognized the
expressed human IGF-1 and not the endogenous murine
one. Detectable levels of human IGF-1 were found in the
spinal cord of aCAR IGF-1 LV-treated mice (mean IGF-1
levels 18.736 ng/mg), while little to no IGF-1 was detected
in nontreated animals, with mean background levels at
2.1 ng/mg (Fig. 4D).
Cross-species neuronal transduction of aCAR
LV
To further investigate the in vivo tropism of the aCAR-
targeted vector and investigate its ability to be retro-
gradely transported, aCAR-targeted and control vectors
were stereotaxically applied to the rat striatum. Details of
the lentiviral preparations produced for striatal injections
are presented in Table S2. Prior to the injection, vectors
were normalized to vector infectivity values to ensure
equal administration of potent lentiviral particles. All rats
received 4 lL of appropriate lentiviral preparation diluted
in formulation buffer (TSSM). Three weeks postinjection
the animals were euthanized and brains were examined
for eGFP expression, indicative of retrograde delivery and
expression of the transgene by the HIV-1-based aCAR-
targeted LV. Figure S3 shows that the aCAR-targeted vec-
tor efficiently delivers the transgene to the site of injection
showing considerable affinity for neurons, though still
transducing a small amount of astroglia. The nontargeted
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control vector (lacking the targeting antibody but still
pseudotyped with neurotropic sindbis-G) did also trans-
duce neurons, however, at lower efficacy as it bears detar-
geting mutations. The aCAR-targeted vector resulted in
retrograde transduction of mytral cells of the OB, a distal
structure connected to the striatum’s olfactory tubercle, as
previously observed by us for other retrogradely trans-
ported vectors.29 No significant transduction of thalamic
nuclei, or pars compacta of the SN was observed though,
which was probably due to the absence of vector uptake
at thalamostriatal and nigrostriatal nerve terminals pre-
sumably due to the absence of aCAR receptors in those
neuronal synapses.
In summary, we observed substantial therapeutic effi-
cacy in vivo with MN-targeted aCAR IGF-1 LV pretreat-
ment with significant delay of disease onset and extension
of survival compared with both VSV-G IGF-1 LV and
nontreated control animals linked to increased survival of
MNs. Efficacy is linked to improved motor performance,
as aCAR IGF-1 LV-treated mice retained muscle tone and
motor function during their prolonged survival.
Discussion
In this study, we report proof of concept studies testing a
novel-targeted LV-expressing IGF-1 for noninvasive neu-
roprotective gene therapy for ALS. IGF-1 is known to
have a neurotrophic effect on motor neurons.30 To date
IGF-1-based therapies have little beneficial effect upon
systemic or intrathecal administration in ALS patients.19–21
The poor outcomes of these studies may possibly be due
to low availability of IGF-1 as free IGF-1 is reduced while
IGF-1R expression is upregulated in both the CNS and
muscle of ALS patients.31,32 Alternative to these
approaches, many studies have focused on distal targeting
of MNs delivering therapeutics through the retrograde
route. Indeed, IGF-1 has previously been reported to pro-
long survival in transgenic mouse ALS models through
viral mediated delivery applied distally,12,14,16 while direct
spinal cord application has had poor outcomes.17,18 We
previously showed that in vivo i.m. delivery of aCAR-tar-
geted vector in mouse leg muscles results in specific retro-
grade transduction of lumbar MNs.22 In the current
study, we utilized the aCAR-targeted vector and investi-
gated the in vivo neuroprotective effects of lentivirally
expressed IGF-1 following intramuscular application to
SOD1G93A mice.
Specifically, we showed that we can produce high titer
preparations of aCAR-targeted LVs that efficiently express
human IGF-1. Utilising ELISA we confirmed expression
of human IGF-1 only in lysates and supernatant of cells
transduced with LVs expressing this factor. Background
levels detected were at least 5 to 20 orders of magnitude
lower than therapeutic LV transduced cells, showing that
synthetic human IGF1-Ea is successfully expressed and
mature IGF-1 is secreted upon transduction of HEK293T
cells with LVs.
The results of this study indicate that IGF-1 trophic
factor delivery to CNS via a one-time i.m. application of
aCAR IGF-1 LVs has significant therapeutic benefit and
can modify disease progression in the SOD1G93A mice.
The advantage of our delivering strategy over existing
approaches resides on high targeting specificity of the LVs
applied distally which overcomes the need of direct injec-
tion into the spinal cord where the affected MNs reside.
Recently a study utilising AAV encoded microRNA
against human SOD1 has shown that suppressing SOD1
in MNs either by intracerebroventicular or by lumbar
intrathecal injections can be neuroprotective.33 In vivo
i.m. application of our targeted therapeutic vector
resulted in human IGF-1 protein expression in the spinal
cord (Fig. 4), which in turn significantly delayed disease
onset and increased mean survival of SOD1G93A mice by
14 days. Efficacy observed was linked to improved motor
performance, as aCAR IGF-1 LV-treated animals retained
muscle tone and motor function during their prolonged
survival. Our current findings are in agreement with simi-
lar studies showing that treatment with this isoform of
IGF-1 is beneficial.11,12 Similar to others14,16 we observed
some variability in survival as not all cohorts of mice
Figure 3. aCAR IGF-1 LV significantly prolonged motor performance in SOD1G93A mice. (A) SOD1G93A mice were tested weekly for rotarod
coordination. The rotarod performance was analysed over time of either only females (n = 12 per group), or only males (n = 12 per group) cohorts.
aCAR IGF-1 LV-treated female mice had better rotarod performance as compared with age-matched controls from 130 days onwards (two-way
ANOVA, Bonferroni post hoc test, ***P < 0.001, *P < 0.05; error bars represent  SEM). aCAR IGF-1 LV-treated male mice had better rotarod
performance as compared with age-matched nontreated controls from 130 days onwards (two-way ANOVA, Bonferroni post hoc test, *P < 0.05;
error bars represent  SEM). No significant difference was observed between aCAR IGF-1 LV and VSVG IGF-1 LV-treated male mice. (B) Dynamic
parameters of gait analysis using manual footprint analysis. Stride length is the distance in millimeters between successive placements of the same
paw. Footprint analysis showed impaired walking patterns in control animals compared to aged-matched P28 aCAR IGF-1 LV-treated mice from
115 days onwards (data represent average values per group  SEM (n = 6 per group); two-way ANOVA, Bonferroni post hoc test, **P < 0.01,
***P < 0.001). (C) Dynamic parameters of gait analysis using digital footprint analysis. Impaired walking patterns in control animals compared to
aged-matched from 125 days onwards (data represent average values per group  SEM (n = 6 per group); two-way ANOVA, Bonferroni post hoc
test, *P < 0.05, ***P < 0.001). aCAR IGF-1 LV-treated mice (n = 24; 12 males and 12 females) are shown in magenta, VSVG IGF-1 LV-treated mice
(n = 12; 6 males and 6 females) are shown in light blue and nontreated (n = 24; 12 males and 12 females) control group in black.
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(regardless of sex) responded equally to i.m. injection of
therapeutic aCAR IGF-1 LV. More specifically, in our ini-
tial cohorts, we observed two female mice that survived
up to 197 and 198 days, respectively, while in a separate
cohort a male mouse survived up to 240 days which
account for extension of survival of up to 27% and 54%,
respectively. So far we are the first to report such a sur-
vival effect. However, when all cohorts tested were com-
bined, mean survival was significantly extended by 14 and
9 days when compared with nontreated and VSVG IGF-1
LV-treated control cohorts, respectively. Although our
sample size was sufficient to detect a medium effect with
80% power, our observations further demonstrate the
necessity of including large animal numbers in order to
detect meaningful therapeutic effect.26 Variability reported
in our study may be attributed to a number of factors
such as: (i) the delivery strategy, as muscle injection can-
not by principle be accurate as far as the injection point
and depth is concerned, (2) the given dose used, as only
50% of particles injected are expected to be functional,22
or (3) even the strength of expression of the transgene



















































































































Figure 4. aCAR IGF-1 LV protects motor neurons in SOD1G93A mice. (A) Histological evaluation of end-stage lumbar spinal cord in nontreated
(top panel) and aCAR IGF-1 LV-treated (bottom panel) SOD1G93A mice. Scale bars 100 lm. (B) Expression of EGFP in spinal cords of two different
end-stage mice injected with the aCAR eGFP LV. Images show the variability observed in MN loss. Scale bars 100 lm. (C) Quantification of
surviving MNs in thoracic and lumbar spinal cord in nontreated, VSVG IGF-1 LV and aCAR IGF-1 LV-treated animals at end-stage classification of
the disease (one-way ANOVA, Tukey’s Multiple Comparison Test, P < 0.05; error bars represent  SEM; n = 8 per group). (D) Human IGF-1 levels
in homogenates of end-stage lumbar spinal cord samples from nontreated (untreated) and aCAR IGF-1 LV-treated animals were measured by
ELISA. Intramuscular delivery of aCAR IGF-1 LV resulted in human IGF-1 expression in spinal cord. Control mice showed no expression of the
human IGF-1 protein.
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Thus, interpreting and comparing the results of various
IGF-1 ALS studies may be challenging even when the
same delivery route is chosen as other factors such as dis-
ease variability linked to the animal model or IGF-1 iso-
form utilized can contribute to this variability.
Sex-specific differences in disease onset and progression
as well as response to therapy have been reported in a
number of studies.17,25,34 In the current study, we found
no significant difference when we compared overall dis-
ease onset and survival between male and female aCAR
IGF-1 LV-treated mice. No significant difference was also
observed in both cases between nontreated and VSVG
IGF-1- treated control groups. To determine whether
neuroprotection can result from retrogradely transported
muscle-produced IGF-1 we included in our study VSVG
IGF-1 LVs injected control cohorts. Interestingly, we
observed differences in disease onset between the treat-
ment groups only in male mice (Fig. 2). Disease onset
was significantly delayed in male aCAR IGF-1 LV-treated
mice when compared with nontreated male mice, how-
ever this was not significant when compared with VSVG
IGF-1-treated male cohort. Unlike males, in female mice,
disease onset was delayed and survival was extended sig-
nificantly in comparison to both control cohorts. Similar
differences in body weight maintenance and motor func-
tion were observed between aCAR IGF-1 LV and VSVG
IGF-1 LV-treated male cohorts (Figs. 2D and 3A). A pos-
sible explanation for this could be that MN rescue by
aCAR IGF-1 LV treatment possibly slowed muscle atro-
phy and consequent weight loss. However, because VSVG
IGF-1 LV-treated male mice also maintained their
weights, it is likely that weight was maintained in IGF-1-
treated mice because IGF-1 had an anabolic effect on the
injected muscles (local expression) and consequently these
mice were better able to feed and perform on the rotarod.
It is known that IGF-1 has a key role both in muscle
and nerve tissue anabolism and consequently locally
enhances muscle and promotes neuronal survival.35–37
The IGF-1 gene, which encodes IGF-1 undergoes alterna-
tive splicing producing multiple isoforms. One of these
isoforms, the IGF-1Ea, which is used in this study, is the
main supply of anabolic agent in the form of mature
IGF-138,39 and is produced by active muscle.40 When pro-
vided as a muscle-specific transgene it results in muscle
hypertrophy and enhances regeneration upon injury.40–42
Several studies have reported that muscle restricted
expression of muscle-specific IGF-1Ea (mIGF-1) isoforms
in SOD1G93A mice resulted in enhanced MN survival,
delayed disease onset, and stabilized the NMJ.11,43,44
Moreover, localized overexpression of IGF-1Ea has been
shown to protect a range of different tissues, including
skeletal muscle, against neurodegenerative diseases with-
out increasing systemic IGF-1 levels.11,45 In a recent study,
Barton and colleagues showed that viral expression of
IGF-1Ea and not of mature IGF-1 promotes the hyper-
trophic response of muscle in vivo.46
Thus, this can explain the effect we observe in VSVG
IGF-1 LV-treated male cohorts both in body weight
maintenance and rotarod performance. A CMV enhancer/
promoter is active in muscle, and upon intramuscular
injection of VSVG IGF-1 LV, the expression of IGF1-Ea
in transduced myofibers can have an anabolic effect on
the injected muscles and consequently allow these mice to
be better able to feed and have disease progression similar
to the aCAR IGF-1 LV-treated ones.
It could be argued that the effect we see in these ani-
mals results from retrogradely transported muscle-pro-
duced IGF-1 having a therapeutic effect in their spinal
cord MNs. However, this possibility can be excluded as
VSVG IGF-1 LV injected male mice do maintain their
body weight, have rotarod performance, and delayed dis-
ease onset similar to age-matched aCAR IGF-1 LV-treated
males but their mean survival is not extended (Figs. 2,
S1). Most importantly, MN survival in VSVG IGF-1 LV-
injected animals was poor compared with the enhanced
MN survival observed as a result of i.m. pretreatment
with aCAR IGF-1 LV (Fig. 4C). These results strongly
implicate that localized expression of IGF-1 in muscle is
beneficial, possibly via a muscle enhancement mechanism
but does not prolong survival.
Additionally, lack of therapeutic effect or sex-restricted
efficacy was observed in studies where the human IGF-
1Ea isoform was overexpressed in muscle47 or upon
intraparenchymal spinal cord delivery17 in SOD1G93A
mice. The male only effect observed in the second study
could not be linked to sex-specific differences17 according
to the authors. Results from the present study demon-
strate that female aCAR IGF-1 LV-treated cohorts
appeared to respond better as far as disease progression
is concerned, maintaining their weights and motor per-
formance when compared with control groups. However,
the extension in survival was similar in both male and
female aCAR IGF-1 LV-treated mice. Additionally, MN
survival and long-lasting human IGF-1 expression in the
spinal cord were seen in both males and females (Fig. 4),
suggesting that the effect was unlikely related to sex-spe-
cific differences.
Unlike most of these studies where IGF-1 is directly
delivered to the muscle, our therapeutic strategy resides
on retrogradely transported IGF-1. Our targeted therapeu-
tic aCAR IGF-1 LV allows delivery of IGF-1 specifically in
the spinal MNs by targeting the CAR receptor at the
NMJ. This way, IGF-1 can be directly delivered to the
spinal cord MNs which express IGF-R,32 and via secretion
possibly establish an autocrine loop, bypassing the risk of
reduced bioavailability of injected IGF-1 by IGFBP.32
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Assessment of aCAR IGF-1 LV dose escalation and
application of treatment at disease onset in this and new
rodent models of disease48 will provide further informa-
tion as to the extent of the therapeutic efficacy that can
be achieved with this targeted therapeutic vector in ALS.
Combinatorial gene therapy utilizing multicistronic LV
vectors expressing additional factors, such as heat shock
proteins49 or miR-206,50 could further enhance the
potency of this approach. As the aCAR antibody
expressed on the LV surface binds both mouse and
human receptors51 testing in iPSC-derived motor neurons
from ALS52 patients could be possible and might enhance
translatability.
In summary, our data highlight a novel noninvasive
strategy to specifically deliver therapeutics into spinal
cord MNs through single distal i.m. injections, and show
for the first time that the antibody-targeted therapeutic
aCAR IGF-1 LV vector is beneficial in disease progression
and survival in a mouse model of ALS at the given dose.
We are the first to report substantial therapeutic efficacy
in vivo with aCAR IGF-1 LV pretreatment where survival
was extended up to 50% compared with VSVG IGF-1 LV
and nontreated controls. These data support that aCAR
IGF-1 LV is a promising candidate for early non-invasive
neuroprotective gene therapy in ALS.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1. Intramuscular delivery of aCAR IGF-1 LV
delayed disease onset and extended survival in both male
and female SOD1G93A mice. (A, left panel) In male
SOD1G93A mice aCAR IGF-1 LV treatment significantly
delayed median disease onset by 29.5 days when com-
pared with nontreated control mice (145 vs. 115.5 days
P < 0.0001 Wilcoxon, signed-rank test). No significant
delay was observed versus VSVG IGF-1-treated mice
(6 days). (A, right panel) In the female SOD1G93A mice,
treatment with aCAR IGF-1 significantly delayed median
disease onset versus both nontreated and VSVG IGF-1-
treated control mice by 32.5 days 9 days (153 vs. 120.5,
P < 0.0001; 153 vs. 144, P = 0.0087) , respectively. (B)
Median survival of both male and female aCAR IGF-1
LV-treated mice, was significantly increased versus non-
treated control cohorts by 12 and 8 days respectively
(males v2 = 8.513, P = 0.0035; females v2 = 7.913,
P = 0.0049). When compared with VSVG IGF-1-treated
cohorts, aCAR IGF-1 LV treatment significantly increased
median lifespan of both female (7.5 days v2 = 4.756,
P = 0.0292) and male mice (4 days; v2 = 4.518,
P = 0.0335).
Figure S2. Graphical output of the digital and manual
systems for gait analysis. Stride length is the distance in
millimetres between successive placements of the same
paw. (A) Representative images of footprint analysis pro-
duced by the Caltwalk digital system showing the walking
pattern of the mouse in the top panel, and a time-based
diagram of the paw prints in the bottom panel. Two rep-
resentative mice (a treated and a nontreated) are pre-
sented at two different stages of the disease:
presymptomatic stage (70 days old) and late symptomatic
stage (135 days old). Prints of paws are marked as RH
(right hind; magenta), RF (right front; light blue), LH
(left hind; green) and LF (left front; yellow). The length
of each bar at the bottom panel indicates the duration of
the stance phase of that particular paw, whereas the space
between bars indicates the duration of the swing phase.
Footprints of late symptomatic stage showed that
untreated SOD1G93A mice dragged hind legs whereas
aCAR IGF-1 LV-treated mice showed minor defects in
coordination of steps. (B) Representative photos of man-
ual footprint analysis of SOD1G93A mice (treated and
nontreated) at late symptomatic stage, showed impaired
walking patterns in nontreated control animals compared
to aged-matched aCAR IGF-1 LV-treated mice. Green
front paws; red hind paws. Shown is one run representa-
tive of five successful runs.
Figure S3. Intrastriatal injections of aCAR GFP LV in
rats. eGFP expression at the site of injection (striatum)
and distal sites (olfactory bulb) injected with aCAR-tar-
geted lentiviral vector. (A) 30 lm thick brain sections
from n = 6 (n = 3 per group) rats harvested at 3 weeks
postinjection were obtained and stained with anti-eGFP
antibody to enhance the eGFP signal (shown in black).
High magnification inserts corresponding to marked
regions (dashed box) of the panoramic section images
indicate the transduction of cell bodies and fibres.
Panoramic section images were captured by epifluorescent
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microscope either with a 109 objective (olfactory bulb)
or 49 objective (striatum). Colour inserts were captured
at site of injection with confocal microscope. Sections
were triple stained, using anti-eGFP antibody shown in
green, antibody to NeuN shown in red, and antibody to
GFAP shown in magenta. (B) Quantification of vector
tropism in the striatum. Scale bars, 50 lm.
Table S1. Experimental design
Table S2. Lentiviral preparations for Intrastriatal injec-
tions
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